Enzymes are essential to life, as they speed up chemical reactions in organisms that would otherwise run too slowly. However, sometimes it is necessary to alter how an enzyme functions. For example, a pharmaceutical company may want to develop a drug that can “turn off” the enzymes that provide cancer cells with energy. Almost all drugs on the market that effect enzymes function by binding to the enzyme at the location where the actual chemical reactions take place. However, there is another type of drug that binds elsewhere on the enzyme but can still alter how the enzyme functions. This is called an “allosteric” binder, and they offer some distinct advantages compared to their counterparts. Unfortunately, there are almost no allosteric drugs on the market. This is because it takes much longer to screen for allosteric drugs compared to their cousins, which makes them undesirable to pursue for pharmaceutical companies. In this work, I present a method that has the potential to screen for allosteric drugs at a rate just as fast as other drugs. Two-dimensional infrared spectroscopy (2D IR) is an incredibly useful technique as it can report how a drug influences an enzyme, allosteric or otherwise. This research uses 2D IR to capture information about the drug – enzyme interactions, and then uses artificial neural networks to determine if the drug is a candidate for further study. The results of these studies provide an avenue for screening a category of pharmaceutical that is virtually unrepresented in the current drug market.